HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes. HTD1801 demonstrated broad beneficial effects in measures of glycemic control, liver injury and cardiovascular risk fac
May 07, 2020
Approvals Support Clinical Trials in China and Canada for HTD1801 in Primary Sclerosing Cholangitis
November 19, 2019
SHENZHEN, CHINA and ROCKVILLE, MD, October 10, 2019 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced that multiple abstracts for HTD1801...
October 10, 2019